In short
A new clinical trial is underway to investigate the effectiveness of Petrelintide, a long-acting amylin analog, in managing weight for individuals with obesity or those who are overweight with related health issues. This study aims to compare different doses of Petrelintide against a placebo to determine its impact on body weight, safety, and how well it's tolerated by participants.
At a glance
- Drug Name
- Petrelintide (also known as ZP8396)
- Purpose
- Weight management for obesity or overweight individuals with related health issues
- Administration
- Once-weekly subcutaneous self-injection
- Study Design
- Randomized, double-blind, placebo-controlled, Phase 2 clinical trial
- Duration
- 54 weeks (including 42-week treatment period)
- Primary Outcome
- Percent change in body weight from baseline to Week 28
- Secondary Outcomes
- Changes in body weight, waist circumference, HbA1c, fasting glucose, hsCRP, and fasting lipids; percentage of participants achieving ≥5% and ≥10% weight loss
- Safety Assessments
- Treatment emergent adverse events (TEAEs) and anti-drug antibodies (ADAs)
What is Petrelintide?
Petrelintide, also known by its experimental name ZP8396, is a new medication being developed to help manage weight in people with obesity or those who are overweight with related health problems. It's designed as a long-acting amylin analog, which means it mimics the effects of a hormone called amylin that plays a role in regulating appetite and metabolism.
How Does Petrelintide Work?
While the exact mechanism isn't fully detailed in the clinical trial information, as an amylin analog, Petrelintide likely works by: Helping to control appetite and reduce food intake Slowing down the emptying of the stomach, which can make you feel full for longer Potentially affecting metabolism and how the body processes nutrients These effects, combined with a reduced-calorie diet and increased physical activity, are intended to help patients lose weight and improve their overall health.
Clinical Trial Details
Petrelintide is currently being studied in a Phase 2 clinical trial. Here are some key details about the study: It's a randomized, double-blind, placebo-controlled trial. This means participants are randomly assigned to either receive Petrelintide or a placebo, and neither the participants nor the researchers know who is getting which treatment during the study. The trial is testing five different doses of Petrelintide against a placebo. The study lasts for about a year, divided into three periods: A 2-3 week screening period A 42-week treatment period A 9-week safety follow-up period
Potential Benefits of Petrelintide
The clinical trial is designed to measure several potential benefits of Petrelintide: Weight loss: The primary goal is to see how much weight people lose compared to their starting weight after 28 weeks of treatment. Sustained weight loss: The study will also look at weight loss after 42 weeks to see if the effects are maintained. Waist circumference reduction: This can be an important indicator of health, especially related to abdominal fat. Improvements in blood sugar control: The study will measure changes in HbA1c (a long-term measure of blood sugar levels) and fasting glucose. Reduction in inflammation: Measured by changes in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body. Improvements in blood lipids: This includes measures of cholesterol and other fats in the blood.
Administration and Dosage
Petrelintide is designed to be taken once a week as a subcutaneous injection. This means it's injected just under the skin, similar to how some diabetes medications are given. Patients in the trial will be taught to self-administer these injections.
Safety and Side Effects
As with any new medication, monitoring for safety and side effects is a crucial part of the clinical trial. The study will track: Treatment emergent adverse events (TEAEs): These are any new medical problems or worsening of existing problems that occur during the trial. Anti-drug antibodies (ADAs): The body's immune system might produce antibodies against Petrelintide, which could affect its effectiveness or safety. The study will monitor for this. It's important to note that as this is an ongoing clinical trial, the full safety profile and potential side effects of Petrelintide are not yet known.